Nguyen BY, Reveille JD. (2009) Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Current Opinion Rheumatology. 2009 Jul;21(4):404-10
Wit, F; Weverling, G; et al. (2002) Incidence of and Risk Factors for Severe Hepatotoxicity Associated with Antiretroviral Combination Therapy. The Journal of Infectious Diseases 2002;186:23–31
Moyle G; Sawyer W; Law M; Amin J; Hill A. (2004) Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clinical Therapy. 2004 Jan;26(1):92-7.
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis (2005) Morbidity and Mortality Weekly Report. September 30, 2005 / Vol. 54 / No. RR-9
Health and Human Services
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Accessed online 11/27/15
HIV and Its Treatment:
What You Should Know: Health Information for Patients (2006). U.S. Department
of Health and Human Services.
Center for Disease Control and Prevention. Morbidity and Mortality Weekly Report. Recommendations and Reports. December 5, 2008/57. Appendix A. AIDS-Defining Conditions.
Accessed 6/8/2008 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.
Department of Health and Human Services. November 3, 2008; 1-139.
Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
Public Health Service Task Force. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. April 29, 2009 Release. Available at http://aidsinfo.nih.gov/contentfiles/Peri_Tables.pdf Accessed 6/1/09
Lesho, E.P., & Gey, D.C. (2003). Managing issues related to antiretroviral therapy. American Family Physician, 68 (4), 675-686
National Institute of Allergy and Infectious Diseases. (2005). HIV Infection and AIDS: An Overview. www.niaid.nih.gov/factsheets/hivinf
National Institute of Allergy
and Infectious Diseases. (2006). Treatment of HIV Infection. www.niaid.nih.gov/factsheets/treat-hiv.htm
National Institute of Allergy and Infectious Diseases. (2003). New Treatment for HIV Infection: Prolonging and Improving Life. www.niaid.nih.gov/publications/discovery
National Institute of Allergy
and Infectious Diseases. (2004). How HIV Causes Aids Infection. www.niaid.nih.gov/factsheets/howhiv
U.S. Department of Health and Human Services. (2004). Side Effects of Anti-HIV Medications.
Mayo Clinic. (2006). HIV/AIDS Treatment. www.mayoclinic.com
Catanzaro, L. (2006). Antiretroviral Quick Guide. HIV ePharmacotherapy Network. School of Pharmacy and Pharmaceutical Sciences University at Buffalo
Watts DH, Covington DL et al. (2004) Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. American Journal of Obstetrics and Gynecology, Volume 191, Issue 3, Pages 985-992
Townsend, C.; Cortina-Borja, M.; et al. (2007) Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in theUnited Kingdom and Ireland. AIDS 2007, 21:1019–1026
Townsend, C; Willey, B; et al. (2009) Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007
SUSTIVA (efavirenz) HIGHLIGHTS OF PRESCRIBING INFORMATION (2009) Bristol-Myers Squibb.
Zhu, J. and Paul, W. CD4 T cells: fates, functions, and faults Blood September 1. 2008 Vol. 112, Issue 5 American Society of Hematology